专利检索 ap:("EyePoint Pharmaceuticals, Inc.") AND inv:"John JANUSZ" 第 1 页

1.

发明申请
COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES 有权

公开(公告)号：US20220274976A1

公开(公告)日：2022-09-01

申请号：US17685802

申请日：2022-03-03

申请人： EyePoint Pharmaceuticals, Inc.

发明人： Kevin PETERS , Robert SHALWITZ , John JANUSZ , Alexander SMITH

IPC分类号： C07D417/12 , C07D277/30 , C07D277/60 , C07D417/04 , C07D277/56 , C07D277/64 , C07D277/28 , A61K9/00 , A61K47/69 , A61K47/40 , A61P27/02 , A61P27/00 , C07K16/22 , A61K47/26 , A61K31/426 , A61K31/427 , A61K31/428 , A61K31/433 , A61K31/4439 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/513 , A61K31/538 , A61K38/17 , A61K39/395

摘要： Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed. Combination therapy with antibodies and PK/PD data are also disclosed.

2.

发明公开
METHODS FOR MANUFACTURE OF SMALL MOLECULE ACTIVATORS OF TIE-2 审中-公开

公开(公告)号：US20240190857A1

公开(公告)日：2024-06-13

申请号：US18257712

申请日：2021-12-17

申请人： EyePoint Pharmaceuticals, Inc.

发明人： John JANUSZ , Jared RANDALL , James COPP

IPC分类号： C07D417/14 , C07D417/04

CPC分类号： C07D417/14 , C07D417/04

摘要： Disclosed herein are compounds effective for modulation of Tie-2 activity and inhibition of HPTP-beta, and methods of preparation thereof. The compounds can provide effective therapy for vascular disorders that can include, for example, retinopathies, ocular edema, and ocular neovascularization.